Back to Explorer

Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff

FinalCenter for Devices and Radiological Health03/03/2013

Description

This document supersedes Non-invasive Pulse Oximeter General Guidance Document, September 7, 1992.The draft of this document was issued on July 19, 2007.

Scope & Applicability

Product Classes

4
Class II devices

Proposed classification for NGS-based tests for germline diseases.

Reprocessed Single-Use Medical Devices

Guidance on validation data for premarket notification submissions

Pulse Oximeter

The primary device subject to labeling and performance recommendations.

Pulse Oximeters

devices with a pulse oximeter function that estimates the amount of oxygen in arterial blood and pulse rate; Medical devices used for non-invasive measurement of blood oxygen saturation; medical devices within the scope of this guidance; manufacturing and processing methods to pulse oximeters with a history of safe use; medical devices subject to the performance testing recommendations; Medical devices used for measuring blood oxygen saturation; medical device subject to the guidance recommendat

Stakeholders

4
Original Equipment Manufacturer

Entity that established original safety and performance specifications

Reprocessor

Entity that replaces or saves components during reprocessing

Healthy volunteers

Possible to conduct the FIH trial in healthy volunteers

Neonates

Youngest pediatric group requiring cautious bridging

Regulatory Context

Attributes

4
SpO2

The displayed oxygen saturation value which may have a range of uncertainty.; pulse oximeter oxygen saturation measurement; Functional oxygen saturation measured by the device; estimated oxygen level reading

Worst-case basis

Performance testing after maximum number of reprocessing cycles

Skin pigmentation

factor that can affect the accuracy of pulse oximeters; Factor affecting pulse oximeter accuracy; evaluating device performance across diverse levels; diverse pigmentation to be evaluated in clinical studies; Factor that may affect the accuracy of oxygen level readings

Moderate Level of Concern

Former risk classification for CADe devices under the superseded guidance.; Typical risk classification for CADe software

Related CFR Sections (5)

Related Warning Letters (10)

  • Clinical Investigator

    Shirish M. Gadgeel, M.D.

    2025-09-09
  • Clinical Investigator

    Mark J. Savant, M.D

    2025-07-15
  • Bioresearch Monitoring Program/Institutional Review Board (IRB)

    United Health Products, Inc.

    2025-05-20
  • Clinical Investigator

    Americo F. Padilla, M.D.

    2025-03-25
  • Institutional Review Board (IRB)

    Armstrong County Memorial Hospital

    2024-11-05
  • Clinical Investigator

    Namita A. Goyal, M.D.

    2024-10-22
  • Institutional Review Board (IRB)

    Louisiana State University Health Science Center IRB

    2024-10-08
  • Bioresearch Monitoring Program/IRB

    Massachusetts Institute of Technology MIT

    2024-07-16
  • Clinical Investigator (Sponsor)

    Angela D. Ritter, M.D.

    2024-06-18
  • Institutional Review Board (IRB)

    New York State Psychiatric Institute IRB

    2024-03-26

See Also (8)